Daily Cosmetic Research Analysis
Three impactful studies shaped today’s cosmetic-focused evidence base: a randomized phase 2 trial found superior patient satisfaction and cosmetic ratings after percutaneous thermal ablation for early-stage breast cancer; a mechanistic study showed that common sunscreen filters form phototoxic glucuronide metabolites in human skin cell models under full-spectrum sunlight; and a meta-analysis reported that omidenepag isopropyl lowers IOP comparably to FP agonists with fewer eyelash/periorbital co
Summary
Three impactful studies shaped today’s cosmetic-focused evidence base: a randomized phase 2 trial found superior patient satisfaction and cosmetic ratings after percutaneous thermal ablation for early-stage breast cancer; a mechanistic study showed that common sunscreen filters form phototoxic glucuronide metabolites in human skin cell models under full-spectrum sunlight; and a meta-analysis reported that omidenepag isopropyl lowers IOP comparably to FP agonists with fewer eyelash/periorbital cosmetic changes but more hyperemia.
Research Themes
- Minimally invasive oncology and cosmetic outcomes
- Sunscreen safety and phototoxicity mechanisms
- Ophthalmic therapeutics with favorable cosmetic side-effect profiles
Selected Articles
1. Cosmetic outcome and patient satisfaction following percutaneous thermal ablation of early-stage breast cancer; results of an open label randomized phase 2 trial.
In a randomized phase 2 treat-and-resect trial (n=41), percutaneous thermal ablation achieved better cosmetic ratings and higher patient satisfaction than subsequent breast-conserving surgery. Ninety-four percent were graded good/excellent by BCCT.core after ablation (vs 80% after surgery), and 91% preferred ablation.
Impact: Establishes patient-centered cosmetic outcomes supporting minimally invasive ablation strategies in early-stage breast cancer, informing shared decision-making.
Clinical Implications: Thermal ablation may be prioritized for eligible early-stage cases where cosmetic outcomes and patient preference are paramount, while awaiting oncologic-equivalence trials for ablation-only strategies.
Key Findings
- In 41 postmenopausal cT1N0M0 patients, cosmetic outcome was rated better after ablation than after surgery (median 1.6 vs 1.8; P=0.07).
- BCCT.core graded 94% of ablation cases as good/excellent vs 80% after surgery.
- Patient satisfaction was high: 95% were satisfied/very satisfied, and 91% preferred ablation over surgery.
Methodological Strengths
- Randomized phase 2 design comparing multiple ablation modalities with standardized assessments
- Use of both patient-reported (BCTOS-13, BREAST-Q) and objective (BCCT.core) cosmetic metrics
Limitations
- Small sample size and open-label design may introduce bias
- Short-term assessment; oncologic outcomes and long-term cosmetic durability not established
Future Directions: Conduct larger, blinded, ablation-only RCTs powered for oncologic non-inferiority and long-term aesthetic/quality-of-life outcomes.
PURPOSE: The aim of the present study is to assess patient reported cosmetic outcome and satisfaction following percutaneous thermal ablation and subsequent breast-conserving surgery. METHODS: Cosmetic outcome and patient satisfaction were assessed in postmenopausal women diagnosed with unilateral invasive cT1N0M0 breast cancer who participated in a randomized phase 2 treat-and-resect trial comparing the efficacy of radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation (CA). Cosmetic outcome was measured subjectively with the BCTOS-13 and the Beast-Q questionnaires (0-100 score), and objectively with BCCT.core software at baseline, after thermal ablation and after surgery. Patient satisfaction was defined as satisfaction with the technique (4 point scale), recommendation of the technique to others (yes/no), and the preference for surgery of thermal ablation after completion of both treatments. RESULTS: Forty-one patients were included in the study. The overall median cosmetic outcome was good after thermal ablation, and intermediate after surgery (1.6 vs 1.8; P = 0.07). Most domains of the BREAST-Q were scored higher after thermal ablation, 95 % of patients were very satisfied or satisfied with the technique, and 91 % would prefer thermal ablation over surgery. Differences between the different techniques were limited On the BCCT.core, 94 % of cases were rated as good or excellent after thermal ablation, compared to 80 % after surgery. CONCLUSION: The present study demonstrates that patient reported and objectivated cosmetic outcomes are good both after thermal ablation and breast-conserving surgery. Patient satisfaction was outstanding following thermal ablation, with a preference for thermal ablation observed in a group of patients who underwent both treatment options.
2. Metabolism of Oxybenzone and Dioxybenzone to Phototoxins in Human Skin Cells.
In two human skin cell models, oxybenzone and dioxybenzone were metabolized to phototoxic glucuronides (≈20–25%) under full-spectrum sunlight, with dose/time-dependent reductions in cell viability. Residual surface filters may provide some shielding, but findings motivate development of UV filters that avoid phototoxic metabolites.
Impact: Provides a mechanistic human-relevant basis for phototoxicity of common sunscreen filters through glucuronidation, informing safety testing and ingredient selection.
Clinical Implications: Safety assessments for sunscreens should incorporate metabolite profiling under full-spectrum light and consider alternatives that do not form phototoxic glucuronides.
Key Findings
- Oxybenzone and dioxybenzone reduced human skin cell viability in a dose- and time-dependent manner under full-spectrum sunlight.
- Approximately 20–25% of each UV filter converted to glucuronide metabolites during permeation through skin cell models.
- Both parent compound and metabolite masses correlated with decreased cell viability, indicating phototoxic contribution of metabolites.
Methodological Strengths
- Dose–response and time–course experiments across two human skin cell models
- Quantification of glucuronide metabolites during permeation under full-spectrum sunlight
Limitations
- In vitro models may not fully capture in vivo exposure and formulation effects
- High concentrations (up to 0.1%) and short exposures may not reflect chronic real-world use
Future Directions: Evaluate in vivo human skin metabolism and phototoxic responses to finished formulations; design and screen UV filters devoid of phototoxic conjugation pathways.
Recent research indicated that exposure of sea anemones in full-spectrum sunlight to the UV filter, oxybenzone, induced increased mortality attributable to the production of phototoxic glucoside metabolites. This study evaluated whether exposure of oxybenzone and dioxybenzone to human skin cell models formed analogous glucuronide conjugates and induced a reduction in cell viability under full-spectrum sunlight. In dose-response evaluations with two human skin cell models, increasing doses of oxybenzone or dioxybenzone (up to 0.1%) or increasing exposure times (up to 24 h) were associated with decreasing skin cell viability. Approximately 20-25% of both UV filters were metabolized to their corresponding glucuronide metabolites during permeation through the skin cell models. The masses of UV filters and their metabolites both were correlated with decreasing skin cell viability. While residual UV filters at the skin surface could shield against such phototoxic effects, these results suggest a benefit to identifying novel sunscreen components that avoid potentially phototoxic glucuronide metabolites.
3. Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis.
Across 17 studies (n=3294 eyes), omidenepag isopropyl reduced IOP similarly to FP agonists but had more conjunctival hyperemia/corneal changes and fewer eyelash and periorbital adverse effects. This provides a cosmetically favorable alternative when FP-related changes are undesirable.
Impact: Integrates efficacy and adverse-event profiles to guide selection of IOP-lowering therapy when cosmetic side effects (eyelash growth, prostaglandin-associated periorbitopathy) are a concern.
Clinical Implications: Consider OMDI 0.002% for patients intolerant to FP-related eyelash/orbital changes, while counseling on higher hyperemia risk; monitor corneal findings and tailor therapy to patient cosmetic priorities.
Key Findings
- No significant difference in IOP reduction versus FP agonists (WMD 0.28 mmHg; P=0.144).
- Significant baseline-to-follow-up IOP reduction with OMDI (WMD -3.78 mmHg; P<.001).
- Higher conjunctival hyperemia (14.0% vs 6.8%) and corneal changes (6.7% vs 3.3%); fewer eyelash (0.0% vs 3.0%) and eyelid/orbital side effects (0.0% vs 2.8%).
Methodological Strengths
- Comprehensive multi-database search with pre-specified models for efficacy and safety
- Inclusion of RCTs and cohort studies with pooled effect estimates and sensitivity analysis
Limitations
- Variable and relatively short follow-up limited long-term and rare AE assessment
- Heterogeneity and inclusion of uncontrolled studies may bias AE estimates
Future Directions: Head-to-head RCTs with longer follow-up to define comparative safety, especially hyperemia and corneal changes, and to identify subgroups benefitting most from OMDI.
PURPOSE: We synthesized the literature to assess the safety and efficacy of Omidenpag isopropyl (OMDI) in comparison to prostaglandin F(FP) agonists used in glaucoma management DESIGN: Systematic review and meta-analysis. METHODS: We searched MEDLINE, EMBASE and CENTRAL from inception to November 2024. Meta-analyses were conducted using fixed-effects models for ocular adverse events (AEs), with pooled risk ratios (RRs), and random-effects models for intraocular pressure (IOP) changes, with weighted mean differences (WMDs). Results are presented as 95% confidence intervals (CIs) and P-values. RESULTS: Of the 358 studies screened, 17 studies (n = 3294 eyes) were included, yielding 5 RCTs, 7 retrospective cohort studies and 5 prospective cohort studies. Most studies were uncontrolled with variable follow-ups (9.3 ± 8.7 months). The mean age was60.8 ± 11.7 years, and 44.73% were male (n = 1318). The primary efficacy outcome was the change in IOP from baseline. 4 studies indicated no significant difference in IOP reduction between OMDI and FP agonists (WMD = 0.28 mmHg, 95% CI [-0.09 to 0.65], P = .144). 17 studies reported a significant reduction in IOP from baseline with OMDI (WMD = -3.78 mmHg, 95% CI [-4.74 to -2.82], P < .001). Overall ocular AEs may have been higher in patients treated with OMDI when compared to FP receptor agonists (RR = 1.16, 95% CI [0.94 to1.43], P = .170), which became significant with the exclusion of 1 study with a marked effect favoring OMDI (1.46 (95% CI: [1.17 to 1.83], P < .001). Incidence of conjunctival hyperemia (14.0% vs 6.8%) and corneal changes (6.7% vs 3.3%) were higher in the OMDI group (P < .05). However, there were less eyelash (0.0% vs 3.0%, P = .003) and eyelid/orbital side effects (0.0% vs 2.8%, P = .013) with OMDI. CONCLUSION: OMDI 0.002% offers an alternative to FPs for IOP management especially when FPs may not be effective or suitable. While its efficacy is comparable, clinicians must consider the increased risk of AEs with OMDI. Short follow-up periods constrained the assessment of long-term efficacy and rare AEs; however, the absence of eyelash-related changes and prostaglandin associated periorbitopathy offers a cosmetic advantage over FPs. Further research could identify patient subgroups who may benefit from OMDI treatment.